Navigation Links
Cardiogenesis Reports First Quarter 2009 Results
Date:5/14/2009

IRVINE, Calif., May 14 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) the "Company", a leading developer of surgical products used in the treatment of patients suffering from severe angina, today reported financial results for its first quarter ended March 31, 2009.

First Quarter 2009 Financial Results

Net revenues in the first quarter of 2009 totaled $2,852,000, a 4% decrease from the prior year first quarter net revenues of $2,982,000. During the first quarter of 2009, the Company sold three lasers and 479 handpiece units as compared to three lasers and 540 handpieces during the first quarter of 2008. The decrease in net revenue for the three months ended March 31, 2009 results primarily from lower handpiece unit volume in the current year quarter.

Richard Lanigan, Cardiogenesis President, stated, "During the fourth quarter of 2008 and through the first quarter of 2009, we implemented an outreach initiative to cardiologists to increase referrals for stand-alone TMR procedures. While we experienced a slow January, the good news is that we added 18 new centers performing stand alone TMR during this period. Success with stand-alone TMR not only increases the case-load for the cardiothoracic surgeons, but may also serve to remind surgeons of the utility of the technology as an adjunct to coronary bypass surgery. We believe the validation of this stand-alone therapy with cardiothoracic surgeons and referring cardiologists is important to the commercial success of TMR."

The Company reported a first quarter 2009 operating loss of $297,000 as compared with an operating loss of $37,000 in the prior year quarter. The net loss for the quarter was $314,000 or $0.01 per basic and diluted share, as compared with a net loss of $36,000, or $0.00 per basic and diluted share in the 2008 first quarter.

The gross margin percentage was 81% of net revenues for the quarter ended March 31, 2009 as compared with an 82% gross margin percentage in the first quarter of 2008. Gross profit decreased by $141,000 to $2,316,000 for the current year quarter as compared with $2,457,000 for the 2008 first quarter.

Research and development expenses were $288,000 in the first quarter of 2009 as compared with $216,000 in the 2008 first quarter. The dollar increase for the three months ended March 31, 2009 was attributed primarily to an increase in activities supporting clinical trials and studies.

Sales and marketing expenses of $1,469,000 in the quarter ended March 31, 2009 decreased $58,000, or 4%, compared with $1,527,000 for the quarter ended March 31, 2008.

General and administrative expenses for the quarter ended March 31, 2009 totaled $856,000 as compared to $751,000 during the quarter ended March 31, 2008. This represents an increase of $105,000, or 14%.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that treat severe angina. The Company's market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR).

For more information on Cardiogenesis and its products, please visit the Company's website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.

Safe Harbor Statement

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's other filings with the Securities and Exchange Commission. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

                             CARDIOGENESIS CORPORATION
                   CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                       (in thousands, except per share amounts)
                                    (unaudited)

                                                   Three months ended
                                                        March 31,
                                                    2009         2008
    Net revenues                                  $2,852       $2,982
    Cost of revenues                                 536          525
                                                   -----        -----
        Gross profit                               2,316        2,457
                                                   -----        -----
    Operating expenses:
      Research and development                       288          216
      Sales and marketing                          1,469        1,527
      General and administrative                     856          751
                                                   -----        -----
        Total operating expenses                   2,613        2,494
                                                   -----        -----
        Operating loss                              (297)         (37)
    Other income (expense):
    Interest expense                                 (10)         (20)
    Interest income                                    1           21
                                                   -----        -----
    Total other (expense) income, net                 (9)           1
                                                   -----        -----
        Loss before income taxes                    (306)         (36)
    Provision for income taxes                         8            -
                                                   -----        -----
        Net loss                                   $(314)        $(36)
                                                  ======        =====
    Net loss per share:
      Basic                                       $(0.01)          $-
                                                 =======        =====
      Diluted                                     $(0.01)          $-
                                                 =======        =====

    Weighted average shares outstanding:
      Basic                                       45,487       45,274
                                                  ------       ------
      Diluted                                     45,487       45,274
                                                  ------       ------

                             CARDIOGENESIS CORPORATION
                       CONDENSED CONSOLIDATED BALANCE SHEETS
                                   (in thousands)

                                                      March 31, December 31,
                                                        2009       2008
                                                    (unaudited)  (audited)
                          ASSETS
    Current assets:
      Cash and cash equivalents                        $2,773     $2,907
      Accounts receivable, net of allowance for
       doubtful accounts of $0 and $20, respectively    1,425      1,330
      Inventories                                       1,125      1,164
      Investments in marketable securities                  -         75
      Prepaids and other current assets                   363        395
                                                        -----      -----
          Total current assets                          5,686      5,871
    Property and equipment, net                           353        382
    Other assets, net                                      18         18
                                                        -----      -----
          Total assets                                 $6,057     $6,271
                                                       ======     ======

            LIABILITIES AND SHAREHOLDERS' EQUITY
    Current liabilities:
      Accounts payable                                   $222       $200
      Accrued liabilities                               1,130      1,103
      Deferred revenue                                    796        800
      Current portion of capital lease obligations          9          6
                                                        -----      -----
          Total current liabilities                     2,157      2,109
    Capital lease obligations, less current portion        21         13
                                                        -----      -----
          Total liabilities                             2,178      2,122
                                                        -----      -----

    Commitments and Contingencies

    Shareholders' equity:
      Preferred stock:
        no par value; 5,000 shares authorized;
         none issued and outstanding                        -          -
      Common stock:
        no par value; 75,000 shares authorized;
         45,487 and 45,487 shares issued and
         outstanding, respectively                    174,043    173,999
      Accumulated deficit                            (170,164)  (169,850)
                                                    ---------  ---------
          Total shareholders' equity                    3,879      4,149
                                                        -----      -----
          Total liabilities and shareholders'
           equity                                      $6,057     $6,271
                                                       ======     ======


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
2. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
3. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
4. Cardiogenesis Corporation to Report Third Quarter 2008 Results on November 13th
5. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
6. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
7. Cardiogenesis Reports First Quarter 2008 Results
8. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
9. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
10. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
11. Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... Stuart Bentkover, ... technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. Bentkover ... unmatched results. , Developed by Cynosure, the PicoSure has been approved by the Food ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of ... A hallmark feature of patients with eating disorders is significant self-criticism, and consequently these ... and obsessions are regarded as maladaptive means for coping with this unease, but also ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June ... Diseases, a continuing medical education (CME) event presented by the Association for Comprehensive ... a first for ACCORD, whose mission is to provide education, tools, and resources ...
(Date:2/5/2016)... Atascadero, CA (PRWEB) , ... February 05, 2016 , ... ... report on the benefits of having a tankless water heater. To view the report, ... of water heaters: tank and tankless. While each has their pros and cons, the ...
(Date:2/4/2016)... Verdes, CA (PRWEB) , ... February 04, 2016 ... ... at the "It's All About YOU Re-Treat" on February 19-21, 2016, in ... Re-Treat" is at Rancho Palos Verdes, California. These 30 professional speakers, including Clinical ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its fiscal year ... --> --> GAAP results: Revenue for ... $5.1 million or 4.1% from the third quarter of ... fourth quarter of 2014. Revenue for the year ended ...
(Date:2/4/2016)... Feb. 4, 2016 In response to the opioid ... Deputy Commissioner for Medical Products and Tobacco, along with other ... the agency,s approach to opioid medications. The plan will focus ... patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure ...
(Date:2/4/2016)... -- --> --> ... Automated External Defibrillator (AED) Market by Product (Semi-Automated External ... Hospitals, Homecare & Nursing Homes) - Forecast to 2019", ... and segments the concerned market with an analysis and ... grow to about $367.0 million by 2019, at a ...
Breaking Medicine Technology: